Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights

Received FDA EUA and CDC recommendation for NVX-CoV2373, marking the first protein-based COVID-19 vaccine authorized in the U.S. for adults; with ...

Related Keywords

Taiwan ,Australia ,Japan ,United States ,New Zealand ,Thailand ,India ,United Kingdom ,Canada ,Switzerland ,Great Britain ,Giovanna Chandler ,Erika Schultz ,Stanleyc Erck ,Us Centers For Disease ,Linkedin ,Prnewswire Novavax Inc ,Coalition For Epidemic Preparedness Innovations ,Nasdaq ,European Union ,Serum Institute Of India ,Novavax Inc ,Clinical Development ,University Of Oxford ,Drug Administration ,World Health Organization ,European Commission ,Clinical Development Program ,Exchange Commission ,Novavax Influenza Program ,European Medicines Agency ,Chief Executive Officer ,Regulatory Strategy ,Emergency Use Authorization ,Disease Control ,Influenza Combination ,Vaccine Candidate Clinical ,Three Months Ended June ,Epidemic Preparedness ,Serum Institute ,Financial Condition ,Novavax Annual Report ,Quarterly Reports ,